Studying How IgE Antibodies Form in Nasal Polyps and Allergic Diseases and How Dupilumab Affects Them

What this Trial Is About

Researchers are investigating how local Immunoglobulin E IgE production occurs in different airway diseases driven by Type 2 inflammation, including allergic asthma, late onset eosinophilic asthma, allergic rhinitis, and chronic rhinosinusitis with nasal polyps. This study aims to uncover the immunological pathways behind mucosal IgE responses and how the drug Dupilumab may influence these processes. Understanding these mechanisms could help develop new treatments for these chronic airway conditions. This observational study focuses on patients with nasal polyposis who are being treated with Dupilumab following usual hospital care. Researchers will collect various tissue samples such as nasal polyps, nasal tissue, and tonsil biopsies from patients with nasal polyps, allergic rhinitis, and related conditions. Using advanced methods like single-cell RNA sequencing, proteomics, and antibody screening, the study will analyze IgE B cell responses and how Dupilumab affects local IgE production. Laboratory cell cultures will also be used to explore how epithelial cells and immune cells interact in these diseases. Participants will undergo sample collections including nasal secretions and tissue biopsies, and their immune cells will be studied in detail using molecular and cellular techniques. Researchers will monitor changes in IgE levels and immune cell behavior during Dupilumab treatment, using flow cytometry and genomic analyses. The study will measure how allergic and non-allergic IgE B cell differentiation occurs over one to two years. The total duration and follow-up vary per participant, with ongoing evaluation of immune responses and local IgE production.

Immunological Mechanisms Underlying Mucosal IgE Responses